Shares of Ligand Pharmaceuticals Inc (NASDAQ: LGN) have risen above the average analyst 12-month target price of $37.39, currently trading at $39.60 per share. This movement has prompted discussions among analysts about potential rating adjustments, with targets ranging from $34.00 to $41.00, contributing to a standard deviation of $2.558.
As of now, the analyst ratings include 11 strong buy ratings, one buy rating, and three hold ratings, with no sell or strong sell ratings reported. The average rating stands at 1.47 on a scale where 1 is strong buy and 5 is strong sell.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
